These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 10638970)
21. Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure. Campbell B; Wirth A; Milner A; Di Iulio J; MacManus M; Ryan G Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1538-45. PubMed ID: 16125872 [TBL] [Abstract][Full Text] [Related]
22. Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR). Nachbaur D; Greinix HT; Koller E; Krieger O; Linkesch W; Kasparu H; Pober M; Hinterberger W; Hausmaninger H; Heistinger M; Ulsperger E; Karlhuber S; Schwinger W; Lindner B Ann Hematol; 2005 Jul; 84(7):462-73. PubMed ID: 15726362 [TBL] [Abstract][Full Text] [Related]
23. The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin's Lymphoma. Muszbek N; Kadambi A; Lanitis T; Hatswell AJ; Patel D; Wang L; Singer JW; Pettengell R Clin Ther; 2016 Mar; 38(3):503-15. PubMed ID: 26856929 [TBL] [Abstract][Full Text] [Related]
24. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer]. Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945 [TBL] [Abstract][Full Text] [Related]
25. Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma. Moser EC; Kluin-Nelemans HC; Carde P; Meerwaldt JH; Tirelli U; Aleman BM; Baars J; Thomas J; van Glabbeke M; Noordijk EM Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1168-77. PubMed ID: 16887289 [TBL] [Abstract][Full Text] [Related]
26. Salvage therapy for Hodgkin's lymphoma. Quddus F; Armitage JO Cancer J; 2009; 15(2):161-3. PubMed ID: 19390313 [TBL] [Abstract][Full Text] [Related]
27. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma. Salar A; Martino R; Perea G; Ribera JM; López-Guillermo A; Guardia R; Escoda L; Altés A; Sierra J; Montserrat E Haematologica; 2002 Oct; 87(10):1028-35. PubMed ID: 12368156 [TBL] [Abstract][Full Text] [Related]
28. Consolidative involved field radiotherapy after high dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma: a case-control study. Oehler-Jänne C; Taverna C; Stanek N; Negretti L; Lütolf UM; Ciernik IF Hematol Oncol; 2008 Jun; 26(2):82-90. PubMed ID: 18085574 [TBL] [Abstract][Full Text] [Related]
29. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma]. Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071 [TBL] [Abstract][Full Text] [Related]
30. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Bessell EM; Graus F; Lopez-Guillermo A; Lewis SA; Villa S; Verger E; Petit J Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):501-8. PubMed ID: 15145169 [TBL] [Abstract][Full Text] [Related]
31. Economics of stem cell transplantation for lymphoma: counting the cost of living. Sweetenham JW Br J Cancer; 2000 Jan; 82(1):4-6. PubMed ID: 10638957 [No Abstract] [Full Text] [Related]
33. A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma. Hosein PJ; Craig MD; Tallman MS; Boccia RV; Hamilton BL; Lewis JJ; Lossos IS Am J Hematol; 2012 Jan; 87(1):111-4. PubMed ID: 22081459 [No Abstract] [Full Text] [Related]
34. Survival in advanced Hodgkin's disease and non-Hodgkin's lymphoma. Rubin AD; Tadros G; Hanley D; Rubin GH; Todd D N J Med; 1996 Oct; 93(10):33-8. PubMed ID: 8918134 [No Abstract] [Full Text] [Related]
35. GM-CSF can hasten recovery of patients with relapsed Hodgkin's disease, at less cost. Oncology (Williston Park); 1992 Apr; 6(4):25. PubMed ID: 1533779 [No Abstract] [Full Text] [Related]
36. [The socioeconomic aspects of the therapeutic measures in lymphogranulomatosis]. Loseva MI; Panacheva LA; Sharaputo VM Vopr Onkol; 1989; 35(11):1361-4. PubMed ID: 2514483 [TBL] [Abstract][Full Text] [Related]
37. Cytokine deregulation in hematological malignancies: clinical and biological implications. Kurzrock R Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2581-4. PubMed ID: 9815659 [TBL] [Abstract][Full Text] [Related]
38. [Multiple organ failure in patients with hemoblastosis during long-term follow-up of treatment]. Loseva MI; Pospelova TN; Gavalova RF; Kurilovich SA; Soldatova GS; Purtova LA; Ianushkevich LA; Ageeva TA; Netesova IG; Mordvov SA Ter Arkh; 1999; 71(7):39-42. PubMed ID: 10481866 [TBL] [Abstract][Full Text] [Related]
39. The cost-benefit ratio of the cure of Hodgkin's disease. Ultmann JE; Ong ST Cancer J Sci Am; 1995; 1(1):23-5. PubMed ID: 9166448 [No Abstract] [Full Text] [Related]